Kohjin Bio
177A.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥4.2bn | ¥4.6bn | ¥4.4bn | ¥4.4bn | ¥3.6bn | ¥3.3bn |
| Operating income | ¥58m | ¥727m | ¥445m | ¥1.1bn | — | — |
| Ordinary income | ¥72m | ¥703m | ¥409m | ¥1.1bn | ¥842m | ¥666m |
| Total assets | ¥7.7bn | ¥8.0bn | ¥6.0bn | ¥5.8bn | ¥5.3bn | ¥4.8bn |
| Net assets / equity | ¥4.9bn | ¥5.0bn | ¥2.8bn | ¥2.7bn | ¥2.0bn | ¥1.4bn |
| EPS (basic) | ¥12.27 | ¥100.93 | ¥50.9 | ¥180.37 | ¥166.59 | ¥2,023.85 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2024-04-01 → 2024-09-30 | Half-year | 45 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 173 figures · EDINET |
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Cell Process Business | ¥975m | ¥80m |
| Microbiological Business | ¥1.4bn | −¥95m |
| Tissue Culture Business | ¥2.5bn | ¥946m |
| Adjustments & eliminations | — | −¥590m |
| Total | ¥4.9bn | ¥932m |
Segment names from EDINET member IDs; not mapped to a common taxonomy.